NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free BIOR Stock Alerts $0.64 +0.03 (+4.92%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.58▼$0.6650-Day Range$0.50▼$1.3352-Week Range$0.48▼$6.70Volume256,333 shsAverage Volume403,018 shsMarket Capitalization$22.96 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biora Therapeutics alerts: Email Address Biora Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,244.5% Upside$15.00 Price TargetShort InterestHealthy3.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.64) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 starsMedical Sector306th out of 929 stocksPharmaceutical Preparations Industry141st out of 438 stocks 3.5 Analyst's Opinion Consensus RatingBiora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiora Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Biora Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.85% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biora Therapeutics has recently decreased by 6.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOR. Previous Next 2.9 News and Social Media Coverage News SentimentBiora Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.97% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biora Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($1.64) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biora Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia is about to pass AppleA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. About Biora Therapeutics Stock (NASDAQ:BIOR)Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More BIOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOR Stock News HeadlinesMay 20, 2024 | globenewswire.comBiora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024May 16, 2024 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16, 2024 | finance.yahoo.comBIOR: BT-600 Data in JuneMay 16, 2024 | msn.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comBiora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...May 15, 2024 | msn.comBiora Therapeutics GAAP EPS of -$0.14 beats by $0.31, revenue of $0.54MMay 15, 2024 | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comBiora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate UpdateMay 6, 2024 | globenewswire.comBiora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024April 30, 2024 | globenewswire.comBiora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600April 18, 2024 | msn.comBiora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51April 15, 2024 | nasdaq.comBiora Therapeutics, Inc. Common Stock (BIOR)April 10, 2024 | stockhouse.comBiora Therapeutics Announces New Patent Covering its BioJet(TM) Liquid Jet Delivery TechnologyApril 9, 2024 | markets.businessinsider.comBiora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery InnovationsApril 8, 2024 | globenewswire.comBiora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery TechnologyApril 4, 2024 | markets.businessinsider.comBiora Therapeutics Gets Positive Interim Data From Clinical Trial Of BT-600 With NaviCap; Stock DownApril 4, 2024 | globenewswire.comBiora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform DevelopmentApril 3, 2024 | globenewswire.comBiora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 2, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | finance.yahoo.comBiora Therapeutics Full Year 2023 Earnings: Beats ExpectationsApril 1, 2024 | msn.comPrecision Biosciences, Mesoblast, Pulse Biosciences among healthcare moversApril 1, 2024 | marketwatch.comBiora Therapeutics Shares Drop 26% After Pricing of Direct OfferingApril 1, 2024 | globenewswire.comBiora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 28, 2024 | seekingalpha.comBiora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call TranscriptSee More Headlines Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+2,244.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,110,000.00 Net MarginsN/A Pretax Margin-20,427.21% Return on EquityN/A Return on Assets-181.49% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.79) per share Price / Book-0.23Miscellaneous Outstanding Shares35,880,000Free Float17,594,000Market Cap$22.96 million OptionableOptionable Beta1.22 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Aditya P. Mohanty M.B.A. (Age 57)CEO & Director Comp: $984.14kMr. Eric d'Esparbes (Age 56)Chief Financial Officer Comp: $748.26kMr. Clarke Neumann J.D. (Age 60)Senior VP, General Counsel & Secretary Comp: $724.62kEric FoxVP of Finance & Accounting & TreasurerMr. George Gianakopoulos (Age 63)Senior Vice President of Sales Ms. Robyn HattonHead of Human ResourcesMr. Kevin Howe Ph.D.Senior VP of Strategic OperationsDr. Sharat Singh Ph.D. (Age 65)Head of Research Dr. Paul Shabram M.B.A.Head of Technical OperationsMs. Ariella Kelman M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsDermTechNASDAQ:DMTKRenalytixNASDAQ:RNLXExagenNASDAQ:XGNEnzo BiochemNYSE:ENZInflaRxNASDAQ:IFRXView All Competitors BIOR Stock Analysis - Frequently Asked Questions Should I buy or sell Biora Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks. What is Biora Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued twelve-month target prices for Biora Therapeutics' shares. Their BIOR share price targets range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 2,244.5% from the stock's current price. View analysts price targets for BIOR or view top-rated stocks among Wall Street analysts. How have BIOR shares performed in 2024? Biora Therapeutics' stock was trading at $1.35 at the beginning of the year. Since then, BIOR shares have decreased by 52.6% and is now trading at $0.6398. View the best growth stocks for 2024 here. Are investors shorting Biora Therapeutics? Biora Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,370,000 shares, a drop of 6.2% from the April 30th total of 1,460,000 shares. Based on an average trading volume of 476,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 3.9% of the shares of the stock are short sold. View Biora Therapeutics' Short Interest. When is Biora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our BIOR earnings forecast. How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Tuesday, March, 26th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.03. When did Biora Therapeutics' stock split? Shares of Biora Therapeutics reverse split on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Biora Therapeutics' major shareholders? Biora Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L and Surbhi Sarna. View institutional ownership trends. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIOR) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
